Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer

Cancer

Volumn 83, Issue 9, 1998, Pages 1980-1988

  Shapiro, Jeremy D ^a   Rothenberg, Mace L ^a,b   Sarosy, Gisele A ^a   Steinberg, Seth M ^a   Adamo, Debra O ^a   Reed, Eddie ^a   Ozols, Robert F ^a,c   Kohn, Elise C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

Chemotherapy; Dose intensive; Ovarian cancer

Indexed keywords

AMIFOSTINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG RESPONSE; FATIGUE; FEMALE; HUMAN; HYPOMAGNESEMIA; LUNG TOXICITY; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVARY CANCER; PRIORITY JOURNAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; REMISSION INDUCTION; SURVIVAL RATE;

EID: 0032212414     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981101)83:9<1980::AID-CNCR14>3.0.CO;2-O     Document Type: Article

References (41)

1. Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer. Devita VT Jr., Hellman S, Rosenberg SA, editor. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott, 1997: 1502-31.
2. Ozols RF, Young RC. Chemotherapy of ovarian cancer. Semin Oncol 1984;11:251-63.
3. Kaye SB, Lewis CR, Paul J, Duncan ID, Gordon HK, Kitchener H, et al. Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992;340:329-33.
4. Kaye SB, Paul J, Cassidy J, Lewis CR, Duncan ID, Gordon HK, et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 1996;14:2113-9.
5. Ngan HYS, Choo YC, Cheung M, Wong LC, Ma HK, Collins R, et al. A randomized study of high-dose versus low-dose cisplatinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Chemotherapy 1989;35: 221-7.
6. Conte PF, Bruzzone M, Carnino F, Gadduci A, Algeri R, Bellini A, et al. High-dose versus low dose cisplatin in combination with cyclophosphamide and epidoxorubicin in sub-optimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol 1996;14:351-6.
7. Ackermann S, Jager W, Merkle E, Martus P, Lang N. Highdose versus low-dose cis-platinum plus treosulfan chemotherapy in advanced epithelial ovarian cancer: results of a prospective randomized trial [abstract]. Proc Am Soc Clin Oncol 1997;16:358a.
8. Jakobsen A, Bertelsen K, Andersen J, Havsteen H, Jakobsen P, Moeller KA, et al. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Oncol 1997;15(1):193-8.
9. Gore ME, Mainwaring PN, Macfarlane V, A'Hern R, Osborne R, Harper P. et al. A randomized study of high versus standard dose carboplatin in patients with advanced epithelial ovarian cancer [abstract]. Proc Am Soc Clin Oncol 1996;15:284.
10. McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML. et al. Assessment of dose-intensive therapy in sub-optimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 1995;13:1589-99.
11. Bella M, Coconni G, Lottici R, Leonardi F, Ceci G, Passalacqua R, et al. Conventional versus high dose-intensity regimen of cisplatin in advanced ovarian carcinoma: a prospective randomized study [abstract]. Proc Am Soc Clin Oncol 1992;11: 223.
12. Bella M, Coconni G, Lottici R, Leonardi F, Ceci G, Passalacqua R, et al. Mature results of a prospective randomized trial comparing two different dose-intensity regimens for cisplatin in advanced ovarian carcinoma. Ann Oncol 1194;5(suppl 8):23.
13. Colombo N, Pittelli MR, Parma G, Marzola M, Torri W, Mangioni C, et al. Cisplatin dose-intensity in advanced ovarian cancer: a randomized study of conventional dose-intense v. standard dose cisplatin monotherapy [abstract]. Proc Am Soc Clin Oncol 1993;12:255 (abstr).
14. Ehrlich CE, Einhorn L, Stehman FB, Blessing J. Treatment of advanced epithelial ovarian cancer using cisplatin, adriamycin and cytoxan, the Indiana University experience. Clin Obstet Gynecol 1983;10:325-35.
15. Hakes TB, Chalas E, Hoskins WJ, Jones WB, Markman M, Rubin SC, et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992;45:284-9.
16. Fennelly D. The role of high-dose chemotherapy in the management of advanced ovarian cancer. Cur Opin Oncol 1996;8:415-25.
17. Bertelsen K, Bastholt L. High-dose platinum chemotherapy in advanced ovarian cancer: a Phase II study. Gynecol Oncol 1992;44:79-82.
18. Van Der Hoop RG, Vecht CJ, Van Der Berg MEL, Elderson A, Boogerd W, Heimans JJ, et al. Prevention of cisplatin neurotoxicity with an ACTH (4-9) analogue in patients with ovarian cancer. N Engl J Med 1990;332:-94.
19. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
20. Calvert AH. Combining cisplatin and carboplatin complementary or contradictory? Ann Oncol 1991;2:89-91.
21. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
22. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclo-phosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and Stage PV ovarian cancer. N Engl J Med 1996;334:1-6.
23. Kohn E, Sarosy G, Davis P, Christian M, Link CE, Ognibene FP, et al. A Phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced stage epithelial ovarian cancer. Gynecol Oncol 1996;62:181-91.
24. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, et al. Amifostine pretreatment for protection against cyclo-phosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996;14:2102-12.
25. Levin L, Simon R, Hryniuk WM. Importance of multi-agent chemotherapy regimens in ovarian carcinoma. J Natl Cancer Inst 1993;85:1732-42.
26. Levin L, Hryniuk WM. Dose-intensity analysis of chemotherapy of advanced ovarian cancer. J Clin Oncol 1987;5: 756-67.
27. Lund B, Hansen M, Hansen OP, Hansen HH. High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease. J Clin Oncol 1989;7:1469-73.
28. Piccart MJ, Nogaret JM, Marcelis L, Longree H, Ries H, Kains JP. et al. Cisplatin combined with carboplatin:a new way of intensification of platinum dose in the treatment of advanced ovarian cancer. J Natl Cancer Inst 1990;82:703-7.
29. Lorusso V. Leone B, Di Vagno G, Manzione L, Palmed S, Vallejo C, et al. Combined carboplatin plus ifosfamide and cisplatin in advanced ovarian cancer: a Phase I-II study [abstract]. Proc Am Soc Clin Oncol 1995;14:267.
30. Fanning J, Hilgers RD. High dose cisplatin/carboplatin chemotherapy in primary advanced epithelial ovarian cancer. Gynecol Oncol 1993;51:182-6.
31. Grem I, O'Dwyer P, Elson P, Simon N, Trump D, Frontiera M, et al. Cisplatin, carboplatin, and cyclophosphamide combination therapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol 1991;10:1793-800.
32. Rothenberg MC, Ozols RF, Glastein E, Steinberg SM, Reed E, Young RC. Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced stage epithelial ovarian cancer. J Clin Oncol 1992;19:727-34.
33. Ozols RF, Ostchega Y, Myers CE, Young RC. High-dose cisplatin in hypertonic saline in refractor ovarian cancer. J Clin Oncol 1985;3:1246-50.
34. Jones A, Wiltshaw E, Harper P, Slevin M, Shepherd J, Mansi J, et al. A randomized study of high versus conventional-dose carboplatin for previously untreated ovarian cancer. Br J Cancer 1992;65(Suppl 16):15.
35. Gershenson DM, Mitchell MF, Atkinson N, Silva EG, Kavanagh IJ, Morris M, et al. The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with epithelial ovarian cancer: "maintenance" therapy reconsidered. Gynecol Oncol 1992;47:7-13.
36. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-peng J, Louie KG, et al. Characteristics of cis-diamminedochloroplatinum-resistant human ovarian cancer cell line and its evaluation of platinum analogues. Cancer Res 1987;47:414-8.
37. Shpall EJ, Stemmer SM, Bearman SI, Bast RC Jr., Peters WP, Ross M, et al. High dose chemo-therapy with autologous bone marrow support for the treatment of epithelial ovarian cancer. In Markman M, Hoskins W, editors. Cancer of the ovary. New York: Williams and Wilkins, 1993:327-38.
38. Stiff PJ, Bayer R, Kerger C, Potkul R, Bayer R, Kerger C, et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997;15(4):1309-17.
39. Fennelly DW, Aghajanian C, Shapiro F, O'Flaherty C, O'Connor K, Curtin JP, et al. Dose escalation of paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer. Semin Oncol 1997;24(1 Suppl 2):26-30.
40. Legros M, Dauplat J, Fleury J, Cure H, Suzanne F, Chassagne J, et al. High-dose chemotherapy with hematopoietic rescue in patients with Stage III to IV ovarian cancer: long-term results. J Clin Oncol 1997;15(4):1302-8.
41. Stiff P, Bayer RA, Camarda M, Tan S, Dolan J, Potkul R, et al. A Phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome. Gynecol Oncol 1995;57:278-85.